Cancer trials versus the real world in the United States

Waddah B. Al-Refaie, Selwyn M. Vickers, Wei Zhong, Helen Parsons, David Rothenberger, Elizabeth B Habermann

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN:: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.

Original languageEnglish (US)
Pages (from-to)438-443
Number of pages6
JournalAnnals of Surgery
Volume254
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Neoplasms
Clinical Trials
Gastrointestinal Neoplasms
National Cancer Institute (U.S.)
Registries
Lung Neoplasms
Physicians

ASJC Scopus subject areas

  • Surgery

Cite this

Al-Refaie, W. B., Vickers, S. M., Zhong, W., Parsons, H., Rothenberger, D., & Habermann, E. B. (2011). Cancer trials versus the real world in the United States. Annals of Surgery, 254(3), 438-443. https://doi.org/10.1097/SLA.0b013e31822a7047

Cancer trials versus the real world in the United States. / Al-Refaie, Waddah B.; Vickers, Selwyn M.; Zhong, Wei; Parsons, Helen; Rothenberger, David; Habermann, Elizabeth B.

In: Annals of Surgery, Vol. 254, No. 3, 09.2011, p. 438-443.

Research output: Contribution to journalArticle

Al-Refaie, WB, Vickers, SM, Zhong, W, Parsons, H, Rothenberger, D & Habermann, EB 2011, 'Cancer trials versus the real world in the United States', Annals of Surgery, vol. 254, no. 3, pp. 438-443. https://doi.org/10.1097/SLA.0b013e31822a7047
Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB. Cancer trials versus the real world in the United States. Annals of Surgery. 2011 Sep;254(3):438-443. https://doi.org/10.1097/SLA.0b013e31822a7047
Al-Refaie, Waddah B. ; Vickers, Selwyn M. ; Zhong, Wei ; Parsons, Helen ; Rothenberger, David ; Habermann, Elizabeth B. / Cancer trials versus the real world in the United States. In: Annals of Surgery. 2011 ; Vol. 254, No. 3. pp. 438-443.
@article{9c734810f85f44e793245dda0dd52786,
title = "Cancer trials versus the real world in the United States",
abstract = "Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN:: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64{\%}) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48{\%} vs 0.67{\%}, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.",
author = "Al-Refaie, {Waddah B.} and Vickers, {Selwyn M.} and Wei Zhong and Helen Parsons and David Rothenberger and Habermann, {Elizabeth B}",
year = "2011",
month = "9",
doi = "10.1097/SLA.0b013e31822a7047",
language = "English (US)",
volume = "254",
pages = "438--443",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cancer trials versus the real world in the United States

AU - Al-Refaie, Waddah B.

AU - Vickers, Selwyn M.

AU - Zhong, Wei

AU - Parsons, Helen

AU - Rothenberger, David

AU - Habermann, Elizabeth B

PY - 2011/9

Y1 - 2011/9

N2 - Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN:: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.

AB - Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN:: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States.

UR - http://www.scopus.com/inward/record.url?scp=80052286823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052286823&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31822a7047

DO - 10.1097/SLA.0b013e31822a7047

M3 - Article

VL - 254

SP - 438

EP - 443

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -